You are here: Industry Insights > AZ

News List

AZ/Merck & Co get new US use for ovarian cancer drug pharmaphorum
December 21, 2018
After several disappointments this year AstraZeneca has ended 2018 on a positive note, gaining a new use for its ovarian cancer drug Lynparza in the US and a first approval in China for its new anaemia drug.
AZ to file potential blockbuster potassium drug in Asia pharmaphorum
December 19, 2018
AstraZeneca is planning filings of its high potassium drug Lokelma in Asia, following supportive trial findings.
AZ begins liver cancer immunotherapy tie-up with AVEO pharmaphorum
December 14, 2018
AstraZeneca has announced a collaboration with US biotech AVEO oncology to investigate a potential cancer immunotherapy combination in liver cancer.
AZ sells rights to RSV virus drug to Sobi for $1.5bn pharmaphorum
December 11, 2018
AstraZeneca has agreed to sell the rights to its drug Synagis (palivizumab) to Swedish Orphan Biovitrum (Sobi) for an upfront $1.5 billion in cash and shares, plus certain conditional payments.
AZ and CRUK team up to go all-in on CRISPR pharmaphorum
December 11, 2018
AstraZeneca and Cancer Research UK are collaborating to launch a centre of excellence in genetic screening, cancer modelling and big data processing that will develop CRISPR technology to better understand the biology of cancer.
AZ’s cancer drug fails again, Roche’s rival gets new use pharmaphorum
December 10, 2018
AstraZeneca’s immunotherapy Imfinzi has failed in another late stage study, while Roche’s rival Tecentriq combination has been approved in the sought-after first line lung cancer indication.
AZ and MSD’s Lynparza shows significant results in ovarian cancer pharmatimes
October 25, 2018
AstraZeneca and MSD’s Lynparza improved progression-free survival by 70% compared to placebo in BRCA-mutated ovarian cancer patients who were in complete or partial response...
AZ/MSD’s Lynparza assigned Orphan status in US pharmatimes
October 19, 2018
AstraZeneca and MSD’s PARP inhibitor Lynparza has been granted orphan drug designation in the US for the treatment of pancreatic cancer.
Novartis, Pfizer, AZ and more hand China 50%-plus cancer drug discounts fiercepharma
October 11, 2018
China is quickly approving many of the newest cancer drugs but it also is demanding big discounts if drugmakers want them on its national insurance coverage list.
AZ and MSD get orphan designation for neurofibromatosis drug pharmatimes
August 06, 2018
The EMA has granted orphan designation to AstraZeneca and MSD's selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1).

Previous page 1 2 3 4 5 Next page